Advancements in AI-driven diagnostics could transform cardiology, enabling autonomous interpretation of up to 80% of cardiac imaging within a decade. David Ouyang, MD, discusses overcoming barriers to running…
NEW YORK (Reuters Health) – The risk of developing post-pericardiotomy syndrome (PPS) in cardiac surgery patients can be halved by treatment with colchicine, an international team has shown.…
NEW YORK (Reuters Health) – A consensus statement compiled by an international panel proposes that the level of platelet reactivity during antiplatelet therapy is a better measure of…
NEW YORK (Reuters Health) – Aortic root dilation is uncommon in highly trained competitive athletes and is not likely to be caused by exercise training. Consequently, aortic root…
NEW YORK (Reuters Health) – In high vascular risk patients, addition of clopidogrel to treatment with acetylsalicylic acid does not help minimize untoward events, researchers report in the…
NEW YORK (Reuters Health) – Despite numerous advances in treatment, evidence-based outpatient therapy for congestive heart failure (CHF) has not improved since 2002, researchers report in the August…
NEW YORK (Reuters Health) – The 10-year outcomes data from the MASS II trial comparing coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) and medical treatment for…
NEW YORK (Reuters Health) – Cardiac resynchronization therapy for a year improves cardiac size and performance in patients with mildly symptomatic heart failure, resulting in improved outcomes, according…
NEW YORK (Reuters Health) – Patients with an acute coronary syndrome referred for invasive treatment have similar outcomes whether they are given double-dose or standard-dose clopidogrel plus higher-dose…
NEW YORK (Reuters Health) – By lowering heart rate, the selective sinoatrial current inhibitor ivabradine improves outcomes in patients with chronic heart failure and an elevated heart rate,…
NEW YORK (Reuters Health) – Patients undergoing percutaneous coronary intervention for acute coronary syndrome initially treated with the synthetic factor Xa inhibitor fondaparinux do not have significantly lower…
